--- title: "The Unbundling of Value: How Platforms and Bottlenecks Redefine Disparate Sectors" type: "News" locale: "en" url: "https://longbridge.com/en/news/295081658.md" description: "The key to understanding market fragmentation lies in value chain mechanics. From Freshworks' AI transition to Sigma Lithium's resource bottlenecks and Beam Therapeutics' R&D platform, we analyze how different business models capture value across unrelated industries." datetime: "2026-08-06T09:15:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295081658.md) - [en](https://longbridge.com/en/news/295081658.md) - [zh-HK](https://longbridge.com/zh-HK/news/295081658.md) --- # The Unbundling of Value: How Platforms and Bottlenecks Redefine Disparate Sectors In analyzing today's deeply fragmented public markets, one must look past the obvious technology aggregators and examine the structural business models underpinning disparate sectors. From enterprise software to industrial mining, the overarching theme is the pursuit of monopolizing a specific layer of the value chain. The economics of bits dictate that marginal costs trend toward zero, making the shift from disparate tools to integrated platforms the primary vector for growth. Take **Freshworks (FRSH.US)**. The IT service management provider is actively moving away from traditional seat-based pricing toward an AI-driven, hybrid monetization strategy. Delivering **USD 237.4M** in Q2 2026 revenue—a **16%** YoY jump—and crossing the threshold into GAAP profitability, Freshworks is effectively increasing switching costs within the SME enterprise layer. Financial architecture functions similarly. **PSQ Holdings (PSQH.US)** is executing a hard pivot from a consumer-facing marketplace into the B2B payments infrastructure space. The strategy is bearing fruit: Q2 2026 revenue from continuing operations skyrocketed **108%** to **USD 7.1M**. Even with a 1-for-15 reverse stock split in July 2026 to appease NYSE listing requirements, the fundamental bet is that its financial infrastructure will become an entrenched API for its clients. Conversely, capital itself can be packaged as a platform, though it remains highly sensitive to macro cycles. **Blackstone Secured Lending Fund (BXSL.US)** operates in the middle-market first-lien debt space. Yet, with Q1 2026 net investment income providing exactly 100% coverage for its USD 0.77 dividend, and non-accruals climbing to **3.1%** of fair value, the model is under pressure. This means that a credit aggregator must rely on flawless underwriting to survive a high-interest-rate environment. This, though, is exactly backwards when evaluating companies constrained by physical atoms, where value is derived from pure scarcity and hard assets. **Sigma Lithium (SGML.US)** sits at the very bottom of the electrification funnel. By producing **35,000 tons** of high-grade lithium concentrate in Q2 2026—beating guidance by **6%**—its operations act as a physical bottleneck that battery manufacturers cannot bypass. We see a similar playbook in aerospace and defense manufacturing. **PMGC Holdings (ELAB.US)** recently confirmed its Nasdaq market-cap compliance while simultaneously investing in its aerospace subsidiaries to lock in long-term manufacturing agreements, aggregating fragmented industrial capacity. Bridging the divide between bits and atoms is **Veea Inc (VEEA.US)**. By partnering with Mexico's Telcel to monetize its edge computing services, Veea is effectively pushing AI processing power out of centralized data centers and into the physical world, creating a localized data fabric. Then there is the most intricate platform of all: human biology. **Neurocrine Biosciences (NBIX.US)** demonstrates the massive cash-generation capability of a mature biotech platform. Raking in **USD 959M** in Q2 2026 revenue, primarily on the back of its core treatments, the company proves that once regulatory hurdles are cleared, neurological solutions scale brilliantly. On the opposite end of the maturity curve is **Beam Therapeutics (BEAM.US)**. While it successfully dosed its first patient in a pivotal global cohort in August 2026, the company recorded **USD 95.1M** in quarterly R&D expenses against just **USD 500K** in revenue. This is the inescapable reality of base-editing platforms: they demand enormous upfront capital to commoditize their underlying genetic technologies. Finally, in the consumer sector, a trusted brand is the ultimate aggregator. **The Honest Co (HNST.US)** is successfully leveraging its clean-formulation brand equity to drive demand, reporting Q2 2026 revenue of **USD 83.3M** and upgrading its full-year outlook. Even legacy IP aggregators like **Hasbro (HAS.US)** depend on their vast libraries of recognizable brands to intermediate the relationship between content creators and family entertainment consumers. Ultimately, sustainable enterprise value is strictly a function of dominating a critical, uncommoditized layer in the value chain. _This article does not constitute investment advice._ ### Related Stocks - [SGML.US](https://longbridge.com/en/quote/SGML.US.md) - [FRSH.US](https://longbridge.com/en/quote/FRSH.US.md) - [HAS.US](https://longbridge.com/en/quote/HAS.US.md) - [PSQH.US](https://longbridge.com/en/quote/PSQH.US.md) - [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md) - [HNST.US](https://longbridge.com/en/quote/HNST.US.md) - [ELAB.US](https://longbridge.com/en/quote/ELAB.US.md) - [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md) - [VEEA.US](https://longbridge.com/en/quote/VEEA.US.md) ## Related News & Research - [Hasbro (NASDAQ:HAS) Director Elizabeth Hamren Sells 1,975 Shares of Stock](https://longbridge.com/en/news/295847712.md) - [Hasbro director Elizabeth Hamren sells 2,964 common shares worth $272,035.43](https://longbridge.com/en/news/295842125.md) - [Assenagon Asset Management S.A. Has $46.78 Million Stock Holdings in Hasbro, Inc. $HAS](https://longbridge.com/en/news/295316935.md) - [Honest (NASDAQ:HNST) Director Andrea Turner Sells 34,396 Shares of Stock](https://longbridge.com/en/news/295589056.md) - [Neurocrine Announces Publication Of Phase 4 KINECT-PRO Study Data For Ingrezza In Tardive Dyskinesia](https://longbridge.com/en/news/295671080.md)